Related Experiment Video

Updated: Jun 19, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Carvedilol in chronic heart failure: past, present and future

Robin Ap Weir1, Henry J Dargie

  • 1Department of Cardiology, Western Infirmary, Glasgow G116NT, Scotland, UK.

Future Cardiology
|October 7, 2009
PubMed

Insights

Beta-blockers like carvedilol are proven safe and effective for heart failure patients, yet remain under-prescribed. This review discusses optimal use and potential advantages of carvedilol in heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Large trials confirm beta-blocker efficacy and safety in chronic heart failure.
  • Carvedilol shows recent benefits in heart failure post-myocardial infarction.
  • Despite evidence, beta-blockers are under-prescribed for heart failure, a growing public health concern.

Purpose of the Study:

  • To guide the initiation and selection of beta-blockers for heart failure.
  • To explore potential advantages of carvedilol over other beta-blockers in heart failure.
  • To consider the future role of beta-blockade alongside device therapies in heart failure.

Main Methods:

  • Review of large randomized clinical trials on beta-blockers in heart failure.
  • Analysis of studies investigating carvedilol's effects, particularly post-myocardial infarction.
  • Discussion of clinical practice guidelines and emerging therapeutic strategies.

Main Results:

  • Bisoprolol, carvedilol, and metoprolol are established as effective and safe in heart failure.
  • Carvedilol demonstrates specific benefits in early heart failure after acute myocardial infarction.
  • Under-prescription of beta-blockers persists despite strong evidence.

Conclusions:

  • Beta-blockers are essential for managing heart failure, with carvedilol being a well-studied option.
  • Optimizing beta-blocker initiation and selection is crucial for improving patient outcomes.
  • The integration of beta-blockade with device therapies may shape future heart failure treatment paradigms.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...